Finished product reference
Corifollitropin Alfa
Injection, Solution · Parenteral · 200 µg/1mL · 0.5 mL
- List code
- 52062
- Pharmacologic class
- Long-acting recombinant follicle-stimulating hormone agonist (gonadotrophin)
What it is and how it works
A recombinant glycoprotein consisting of the FSH alpha subunit and a beta subunit extended with the C-terminal peptide of hCG, giving a prolonged half-life. A single injection provides sustained FSH activity that initiates and maintains multifollicular development for the first 7 days of ovarian stimulation.
Indications
Controlled ovarian stimulation in combination with a GnRH antagonist for the development of multiple follicles in women participating in assisted reproductive technology programmes; in some markets also induction of spermatogenesis in adolescent males with hypogonadotropic hypogonadism (with hCG).
Dosage and administration (summary)
Women: a single subcutaneous injection on stimulation day 1, typically 100 micrograms for body weight 60 kg or less and 150 micrograms for body weight above 60 kg, under the supervision of a fertility specialist; daily FSH may follow from day 8 if required.
Contraindications
Tumours of the ovary, breast, uterus, pituitary or hypothalamus; abnormal vaginal bleeding without known cause; primary ovarian failure, ovarian cysts or enlarged ovaries; history of ovarian hyperstimulation syndrome (OHSS) or a previous cycle with more than 30 follicles; polycystic ovarian syndrome.
Warnings and precautions
Ovarian hyperstimulation syndrome can occur and patients should be monitored by ultrasound. Multiple pregnancy, ectopic pregnancy and thromboembolic events are increased with assisted reproduction. Use is not recommended with a GnRH agonist protocol.
Pregnancy
Not indicated during pregnancy.
Storage and supply
Store refrigerated at 2–8 °C, do not freeze; may be kept at or below 25 °C for up to 1 month; protect from light.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.